



Collaborative Working Executive Summary

Published on www.bayer.co.uk

Project title	Improving Prostate Cancer Services at Mount Vernon Cancer Centre (IPCS Project) – Joint Working
Project partners	Mount Vernon Cancer Centre (MVCC) Bayer Plc
Project summary	<p>The aim of the project is to increase capacity and provide rapid access to prostate cancer services through the introduction of two additional out-patient clinics, one at Mount Vernon Cancer Centre and the second one at West Hertfordshire Teaching Hospitals NHS Trust (WHHT) – St Albans site. The current consultant out-patients’ clinics are oversubscribed meaning that consultant clinic slots are not long enough to conduct patient consultations as they would like to. The additional clinics will enable the Oncology Pharmacy Non-Medical Prescriber to manage the less complex non-metastatic patients and the consultant can dedicate their time to the more complex metastatic prostate cancer patients. This would ensure that all patients have the required amount of time with the appropriate healthcare professional.</p>
Expected benefits to patients/patient care/NHS and Bayer	<p>Expected benefits for patients are:</p> <ul style="list-style-type: none">• Aims to increase rapid access to prostate cancer services by increasing available appointments per week.• Aims to improve prostate cancer patients’ awareness of service options available through appropriate patient communications.• Intends to create a thorough understanding of their disease state and aid self-management and adherence to treatment through improved patient counselling by the non-medical prescribing pharmacist.• Aims to deliver treatment closer to home for prostate patients. <p>Expected benefits for the Trust are:</p> <ul style="list-style-type: none">• Aims to provide Oncology Pharmacy Non-Medical Prescriber led out-patient clinics for less complex non-metastatic prostate cancer patients receiving treatment, which intends to facilitate the following service improvements:<ul style="list-style-type: none">○ Increased number of prostate out-patient clinic consultations.○ Increase the number of non-metastatic patients seen by the Oncology Pharmacy Non-Medical Prescriber to free up time for consultants to see more complex cases.○ Improve patient services by developing a method that will enable them to be seen in the right clinic for their needs (less complex

	<p>patients to be seen by a Non-Medical Prescribing Pharmacist and more complex patients to be seen by the consultant).</p> <ul style="list-style-type: none"> • Opportunity to share outputs, best practice and learning through a publication within the Oncology community illustrating the Oncology Pharmacist led out-patient clinic service development and quality of care improvements to provide evidence for a long-term financially sustainable service nationally in the oncology community. <p>Expected benefits for Bayer are:</p> <ul style="list-style-type: none"> • Aims to demonstrate a successful partnership with the NHS team on a collaboration, which has the potential to be shared and adopted by other Hospital / NHS sites. • Aims to gain a richer understanding of planning and implementing prostate cancer services within the context of Oncology Pharmacist Non-Medical Prescriber led out-patient clinic service innovation. This will enrich Bayer’s discussions with other Hospital / NHS sites when developing other Collaborative Working Projects. • Increasing capacity and efficiency aims to ensure treatment is in line with NICE guidelines. (Bayer has a NICE approved treatment in this therapy area). • Opportunity to share outputs, best practice and learning from the collaboration within the oncology community to support service improvement in other locations. • Aims to increase quality of care and patient satisfaction which aims to help patients increase compliance and adherence to treatment.
Start date	September 2022

Date of Preparation: July 2022

Job bag number: RP-UN-ONC-GB-0084